Anti-obesity weight loss medications: Short-term and long-term use.
Long term
Obesity
Short term
Weight loss drugs
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
received:
06
06
2022
revised:
13
07
2022
accepted:
15
07
2022
pubmed:
24
7
2022
medline:
24
8
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
As obesity prevalence increases, more and more drugs that assist with weight loss have been developed. Numerous weight loss drugs had been approved, but many have also been withdrawn based on their lack of efficacy as well as safety concerns. Initial approaches in developing weight loss drugs was by increasing physiological energy expenditure and suppressing the appetite. Subsequently, as more physiological mechanisms for weight gain has been unearthed, drugs targeting newly discovered receptors and/or enzymes have been introduced with improved safety profiles and fewer psychological adverse events. Additionally, drugs targeting hunger or satiety signaling have been actively studied, and have shown increased adoption by physicians. Studies have also evaluated drugs that target metabolic tissues-such as adipose tissue or muscle-to promote weight loss, however to-date nothing has carried on into clinical practice. Starting with a brief history of early obesity treatments, this review evaluates current weight loss pharmaceutical options based on their duration of therapy status.
Identifiants
pubmed: 35870619
pii: S0024-3205(22)00525-2
doi: 10.1016/j.lfs.2022.120825
pii:
doi:
Substances chimiques
Anti-Obesity Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
120825Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.